BeiGene Ltd (ONC) Stock Forecast & Price Target

BeOne Medicines is supported by powerful fundamentals, led by BRUKINSA, which generated about $1.25B in global sales in 2Q26, grew 31% year over year, and remains the top-selling BTK inhibitor while driving 74% of 2025 revenue. The company’s 2Q26 revenue of $1.7B, raised full-year guidance to $6.6-$6.8B, and $5.28B cash balance underscore improving operating leverage and financial flexibility, while BEQALZI and TEVIMBRA add early diversification. Its outlook is further strengthened by more than 50 drugs in clinical trials, five solid-tumor programs advancing toward pivotal development, and a broad late-stage pipeline that can extend growth beyond BRUKINSA.

BeOne Medicines is exposed to meaningful fundamental risk because its bear case assumes sonro fails in Phase 3, never advances toward registration, and its broader platform success probability falls to 5%, underscoring how heavily valuation depends on a narrow set of clinical outcomes. The company also faces intensifying BTK competition around BRUKINSA, while weaker-than-expected results from other early- and mid-stage assets would limit pipeline diversification and leave the business overly dependent on a single product that generated 74% of total revenue in 2025. In addition, its outlook is constrained by regulatory and sector risk, since FDA timing, approval uncertainty, and shifting biotech risk appetite can pressure the stock even if operational execution remains solid.